Connect your AI

TG Therapeutics TGTX Deferred Tax Assets

Deferred Tax Assets at other companies

Bristol-Myers SquibbBMY

$5.18B+29.5%

Johnson & JohnsonJNJ

$6.73B-20.8%

BiogenBIIB

——

Krystal Biotech, Inc.KRYS

——

Neurocrine BiosciencesNBIX

——

Eli LillyLLY

——

Other financials

Income statement

Revenue$204.9M+69.6%

Gross profit$171.4M+62.8%

Operating income$34.8M+304%

Net income$19.8M+291%

EPS (diluted)$0.12+300%

Balance sheet

Cash & equivalents$442.2M+235%

Total debt$753.6M+197%

Total equity$583.1M+146%

Total assets$1.5B+133%

Cash flow

Operating cash flow-$17.9M+37.7%

CapEx$51.0K+104%

Free cash flow-$17.9M+37.6%

Valuation

Market cap$8.15B-14.3%

Enterprise value$8.46B-11.1%

P/E17.6×-225×

P/S11.6×-13.0×

Profitability

Gross margin83.1%-4.4pp

Operating margin21.3%+5.9pp

Net margin66%+55.8pp

FCF margin-6,328.4%+4,773pp

Returns & leverage

Return on equity112.6%+92.9pp

Debt / equity1.3×+0.2×

Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's deferred tax assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is TG Therapeutics's deferred tax assets?: TG Therapeutics (TGTX) reported deferred tax assets of $344.14M in Q1 2026.